bactrim ds- sulfamethoxazole and trimethoprim tablet bactrim- sulfamethoxazole and trimethoprim tablet
sun pharmaceutical industries, inc - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 800 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of bactrim (sulfamethoxazole and trimethoprim) tablets and other antibacterial drugs, bactrim (sulfamethoxazole and trimethoprim) tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. urinary tract infections for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, morganella morganii , proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination
dbl™ sulfamethoxazole 400mg and trimethoprin 80mg concentrate injection
pfizer new zealand limited - sulfamethoxazole 80 mg/ml; trimethoprim 16 mg/ml - solution for injection - 480 mg/5ml - active: sulfamethoxazole 80 mg/ml trimethoprim 16 mg/ml excipient: propylene glycol purified water
sulfamethoxazole and trimethoprim injection
mylan institutional llc - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 80 mg in 1 ml - sulfamethoxazole and trimethoprim injection is indicated in the treatment of pneumocystis jirovecii pneumonia in adults and pediatric patients two months of age and older. sulfamethoxazole and trimethoprim injection is indicated in the treatment of enteritis caused by susceptible strains of shigella flexneri and shigella sonnei in adults and pediatric patients two months of age and older. sulfamethoxazole and trimethoprim injection is indicated in the treatment of severe or complicated urinary tract infections in adults and pediatric patients two months of age and older due to susceptible strains of escherichia coli, klebsiella species, enterobacter species, morganella morganii, proteus mirabilis and proteus vulgaris when oral administration of sulfamethoxazole and trimethoprim injection is not feasible and when the organism is not susceptible to single-agent antibacterials effective in the urinary tract. to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethox
sulfamethoxazole and trimethoprim injection, solution, concentrate
teva parenteral medicines, inc. - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 80 mg in 1 ml - sulfamethoxazole and trimethoprim injection is indicated in the treatment of pneumocystis jirovecii pneumonia in adults and pediatric patients two months of age and older. sulfamethoxazole and trimethoprim injection is indicated in the treatment of enteritis caused by susceptible strains of shigella flexneri and shigella sonnei in adults and pediatric patients two months of age and older. sulfamethoxazole and trimethoprim injection is indicated in the treatment of severe or complicated urinary tract infections in adults and pediatric patients two months of age and older due to susceptible strains of escherichia coli, klebsiella species, enterobacter species, morganella morganii, proteus mirabilis and proteus vulgaris when oral administration of sulfamethoxazole and trimethoprim injection is not feasible and when the organism is not susceptible to single-agent antibacterials effective in the urinary tract. to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxa
sulfamethoxazole and trimethoprim- sulfamethoxazole and trimethoprim tablet
kaiser foundation hospitals - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets, usp and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. urinary tract infections: for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, morganella morganii , proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. ac
sulfamethoxazole and trimethoprim - sulfamethoxazole and trimethoprim tablet
lucid pharma llc - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv) - sulfamethoxazole 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets, usp and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. urinary tract infections for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli, klebsiella species, enterobacter species, morganella morganii, proteus mirabilis and proteus vulgaris. it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination.
sulfamethoxazole and trimethoprim- sulfamethoxazole and trimethoprim tablet
glenmark generics inc. usa - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 400 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets usp and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. urinary tract infections: for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, morganella morganii , proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. acute ot
sulfamethoxazole and trimethoprim double strength- sulfamethoxazole and trimethoprim tablet
new horizon rx group, llc - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 800 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets, usp and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets, usp should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. urinary tract infections: for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, morganella morganii , proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. ac
sulfamethoxazole and trimethoprim- sulfamethoxazole and trimethoprim tablet
preferred pharmaceuticals, inc - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 800 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to empiric selection of therapy. urinary tract infections: for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli , klebsiella species, enterobacter species, morganella morganii , proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. acute otitis med
sulfamethoxazole and trimethoprim- sulfamethoxazole and trimethoprim tablet
preferred pharmaceuticals, inc. - sulfamethoxazole (unii: je42381tnv) (sulfamethoxazole - unii:je42381tnv), trimethoprim (unii: an164j8y0x) (trimethoprim - unii:an164j8y0x) - sulfamethoxazole 800 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of sulfamethoxazole and trimethoprim tablets and other antibacterial drugs, sulfamethoxazole and trimethoprim tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. urinary tract infections for the treatment of urinary tract infections due to susceptible strains of the following organisms: escherichia coli, klebsiella species , enterobacter species, morganella morganii, proteus mirabilis and proteus vulgaris . it is recommended that initial episodes of uncomplicated urinary tract infections be treated with a single effective antibacterial agent rather than the combination. acute otitis medi